Formulation and In-Vitro Evaluation of Liquisolid Compact of Pioglitazone HCL

Zameer, S (2018) Formulation and In-Vitro Evaluation of Liquisolid Compact of Pioglitazone HCL. Masters thesis, College of Pharmacy, Madurai Medical College, Madurai.


Download (6MB) | Preview


The purpose of the study was to formulate liquisolid tablets of Pioglitazone hydrochloride to improve the solubility and dissolution rate. The λmax of Pioglitazone hydrochloride was found to be 234nm in phosphate buffer ph 7.4. The Pioglitazone hydrochloride obeys Beer’s law within the concentration range of 5-25 (μg/ml). The solubility studies were observed that the Pioglitazone hydrochloride have highest solubility in Tween 80 compared to other non-volatile liquid vehicles. FT-IR showed that there was no interaction between the drug and excipients. The DSC thermogram of Pioglitazone hydrochloride and liquisolid compacts, the sharpendothermic peak of pure drug appeared at 187oC, whereas no such peak was observed in liquisolid formulation, which indicates that Pioglitazone hydrochloride was molecularly dispersed and in an amorphous form. Flowable liquid retention potential (Ф-value) was used to formulate liquisolid tablets of Pioglitazone hydrochloride. The twelve formulations were prepared using different concentration of drug in liquid medication, and different ratio of microcrystalline cellulose & aerosil 200 and crospovidone. The directly compressed tablets were prepared using microcrystalline cellulose and aerosil 200 and crospovidone, without addition of non-volatile liquid vehicle. The results of precompression studies which indicates that the prepared powder blend of all the formulations possess good flow properties. The postcompression evaluations such as hardness, thickness, weight variation, friability, drug content and disintegration test of all the formulated liquisolid tablets were within the acceptable limits. In vitro dissolution studies of all the formulations showed immediate release of drug. Among 12 formulations F12 was selected as a best formulationwhich had the better release of drug (98.74%) and subjected to further studies. The in vitro release studies revealed that the liquisolid tablets showed a faster drug release compared to the pure drug and directly compressed tablets. The results of the powder X- ray diffraction studies proved that the crystallinity of pure drug was remarkably reduced in the best formulation. The dissolution rate (DR) in 10 min, increased in linear manner with increasing ratio of drug: Tween 80. The selected formulation showed higher release profile than the pure drug and directly compressed tablets. The selected formulation was found to be stable under the storage condition CONCLUSION: The liquisolid tablet technique can be effective way for dissolution rate improvement of water insoluble drugs such as Pioglitazone hydrochloride. Tween 80 was used as a liquid vehicle. The liquid vehicle plays a contributing role in improving the dissolution profiles of a water insoluble drug in the liquisolid formulations, besides choosing a suitable liquid vehicle according to its viscosity and HLB value. Enhanced dissolution rates obtained in the present study in turn indicates increase in oral bioavailability due to increased wetting and surface area available for dissolution. Hence we can conclude that liquisolid tablets of paliperidone was prepared by using Tween 80 (1:1 ratio of drug and Tween 80) and 20 ratio of microcrystalline cellulose and aerosil 200 provide greater release of drug (98.74 % in 60 mins) among all the formulations, and this ratio can be used to enhance the solubility and dissolution rate of poorly water soluble drug pioglitazone hydrochloride. This novel approach to the formulation may be helpful to improve oral bioavailability.

Item Type: Thesis (Masters)
Additional Information: Reg.No: 261611309
Uncontrolled Keywords: Formulation and In-Vitro Evaluation of Liquisolid Compact of Pioglitazone HCL
Subjects: PHARMACY > Pharmaceutics
Depositing User: Subramani R
Date Deposited: 01 May 2019 12:18
Last Modified: 01 May 2019 12:18

Actions (login required)

View Item View Item